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Background: The nodal status is a strong predictor for cancer specific death in patients with penile carcinoma, and
the C-reactive protein (CRP) level at diagnosis has recently been shown to be associated with poor clinical outcome
in various solid malignancies. Therefore, this retrospective study was performed to evaluate the association between
preoperative CRP levels and the incidence of nodal metastasis in patients with squamous cell carcinoma (SCC) of
the penis.
Methods: The analysis included 51 penile cancer patients who underwent either radical or partial penectomy for
pT1-4 penile cancer between 1990 and 2010. The nodal status was correlated with patient and tumor specific
characteristics.
Results: Sixteen (31%) patients had lymph node metastasis at the time of penile cancer surgery. Nodal status was
associated with tumor stage but did not correlate significantly with tumor grade. In contrast, high presurgical CRP
levels were significantly associated with the diagnosis of nodal involvement (p = 0.04). The optimal CRP cut-off
value to predict lymph node metastasis was set at 20 mg/l based on ROC analysis.
Conclusions: Since a high preoperative serum CRP level was closely correlated with nodal disease, it could be used
as an additional marker to help identify patients with penile cancer who may benefit from inguinal lymph node
dissection.
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Squamous cell carcinoma (SCC) of the penis, which
accounts for >95% of penile cancer cases, is relatively
uncommon in the Western world, but its incidence
has increased slightly and varies markedly in some parts
of Europe with an annual rate of 0.5 to 1.6 per 100,000
men. Its incidence in the United States is affected by race
and ethnicity, being low for Asian-Pacific Islanders and
American Indians and highest for Hispanics and Southern
Blacks [1,2]. The most important prognostic factor in SCC
of the penis is inguinal lymph node involvement [2,3].
Optimal management of patients with impalpable or
even palpably enlarged nodes has been under debate for
many years [4,5]. Various approaches advocated in the* Correspondence: steffens.sandra@mh-hannover.de
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reproduction in any medium, provided the orpast include close surveillance, dynamic sentinel node
biopsy, modified lymphadenectomy, and risk-adapted or
elective lymphadenectomy [3,6]. Each approach has its
advantages and disadvantages. Early resection definitely
offers a survival benefit [2,7], but unfortunately, patients
who undergo inguinal lymphadenectomy are prone to
short- and long-term morbidity [8]. Although the thera-
peutic benefits outweigh these complications in patients
with pathologic nodal involvement [9], only 20% of those
with impalpable lymph nodes harbor occult metastasis
[3,10]. Prophylactic inguinal lymph node dissection in all
these patients would expose many of them to increased
morbidity without offering much benefit. Moreover, up to
50% of all palpable inguinal nodes at diagnosis of penile
cancer are caused by inflammatory reactions [2,11].
The high morbidity associated with inguinal lymph
node dissection combined with a high rate of negative
histopathological findings accounts for the fact thatral Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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when indicated according to all current guidelines (higher
risk factors, e.g. tumor stage ≥ pT1b) [12].
Classical molecular markers are of no clinical value in
SCC of the penis. The soluble eptithelial antigen SCC lacks
sensitivity in the detection of small tumor burdens and has
little prognostic significance for survival after surgery [13].
The detection of lymph node metastases has been associ-
ated with the overexpression of p53 and Ki-67, as well as
loss of membraneous E-cadherin, but these markers are
not useful in clinical practice [2,14].
C-reactive protein (CRP) is an acute-phase reactant to
microbial infection, trauma, infarction, autoimmune dis-
eases or malignancies [15]. High levels of circulating CRP
have recently been associated with metastatic disease and a
poor prognosis in various malignancies [16-26], including
renal cell carcinoma [27,28], urothelial carcinoma [29,30],
castration-resistant prostate cancer [31], and even penile
cancer [26].
This retrospective two-center study was initiated to
evaluate the impact of CRP levels at diagnosis on lymph
node metastasis in patients with penile cancer.Methods
Patient and tumor characteristics
The 51 patients included in this study had complete
patient and tumor characteristics, including the preopera-
tive CRP level, and underwent surgery for penile cancer
between 1990 and 2010 at the Ulm (n = 24) or Hannover
(n = 27) University Medical Centers. The study was ap-
proved by the Ulm University ethics committee (proposal
no. 241/12). All research has been carried out according to
the current Helsinki Declaration (59th edition, Seoul, Korea,
2008; www.wma.net/en/30publications/10policies/b3). The
histological tumor subtype was determined according to
the 2010 UICC Classification. Patient and tumor character-
istics obtained from our computerized institutional data-
bases included age, stage, regional lymph node involvement
or distant metastasis, histological subtype, tumor grade,
CRP value, and body mass index (BMI) as well as rural vs.
urban residential area. The median (mean) follow-up was
27 (37) months; follow up data were evaluable for n = 49
patients.Statistical methods
Continuous variables were reported as the mean and the
interquartile range (IQR). Chi-square and Fisher’s exact
tests were conducted to assess correlations between the
distribution of covariates and nodal involvement. Mann–
Whitney tests were applied to compare continuous cardinal
parameters between the two groups, i.e. patients with and
without lymph node metastasis.Receiver operating characteristic (ROC) curves were
plotted to assess the potential of preoperative CRP for
predicting lymph node involvement.
SPSS 19.0 was used for statistical analysis. A two-tailed
p value less than 0.05 was considered significant in all
tests.
Results
Patient and tumor characteristics
Our patient population comprised 51 men with a mean
age of 62.9 (33–88) years who suffered from SCC of the
penis and underwent penile cancer surgery. 34 patients
(67%) lived in rural and 17 (33%) in urban areas.
The total patient population had a mean body mass
index (BMI) of 27.2 kg/m2 (IQR, 24.2 – 29.8 kg/m2) and
a mean CRP value of 16.2 mg/l prior to surgery. Thus
25 (49%) patients presented with CRP values within the
normal range (<5 mg/l), while 26 (51%) patients had an
elevated CRP value at the time of penile surgery. Thirty-
two of all patients (63%) suffered from locally advanced
penile cancer (≥pT2); nodal disease was seen in 16 cases
(31%) and distant metastasis in 4 cases (8%) at the time
of surgery.
Table 1 gives a detailed summary of patient and tumor
characteristics, including stage and grade.
Association between lymph node involvement and
patient or tumor characteristics
Lymph node metastasis did not correlate with age (p = 0.9,
Mann–Whitney test) or BMI (p = 0.9, Mann–Whitney test)
(cf. Table 1). Moreover, the nodal status was not statistically
significantly related to the residential area (rural vs. urban;
p = 0.5, Fisher’s exact test) or tumor grade (p = 0.1, chi2
test; Table 1). In contrast, the presence of lymph node
involvement was significantly associated with tumor stage
(p = 0.01, chi2 test). Only patients with nodal involvement
had simultaneous visceral metastasis (p = 0.01, Fishers’
exact test).
In addition, the mean CRP value was significantly higher
in patients with nodal disease than in those without it:
24.7 mg/dl vs. 12.4 mg/dl (p = 0.04, Mann–Whitney test).
Receiver operating characteristic (ROC) analysis showed
that the AUC (95% CI) of the CRP value was 0.68 (0.51 –
0.85; p = 0.04) for lymph node metastasis at the time of
penile surgery. Moreover, this analysis revealed an optimal
CRP cut-off of 20 mg/l for predicting lymph node
metastasis.
Twenty-four patients presented with palpable and
clinically suspicious inguinal lymph nodes at the time of
penile surgery. Ultimately, 16 (67%) of them had metastasis
in the histological specimen after lymph node dissection.
The mean CRP value was higher in patients with clinically
suspicious and tumor-positive nodes than in those
whose inguinal lymph nodes were clinically suspicious
Table 1 Association between different patient or tumor variables and nodal metastasis
Variable LN negative LN positive p-value Test
Age, mean [years] (IQR)1 62.5 (56.0-71.5) 63.8 (61.3-68.4) 0.9 Mann–Whitney
BMI, mean [kg/m2] (IQR)1 27.5 (24.1-30.3) 26.7 (26.1-28.4) 0.9 Mann–Whitney
Residential area 0.5 Fisher’s exact
Urban 12 (35%) 4 (25%)
Rural 22 (65%) 12 (75%)
Stage 0.01 Chi2
pT1 15 (43%) 4 (25%)
pT2 15 (43%) 5 (31%)
pT3 3 (9%) 5 (31%)
pT4 2 (6%) 2 (13%)
Pulmonal/visceral metastasis1 0.01 Fisher’s exact
M0 33 (100%) 12 (75%)
M1 0 4 (25%)
Grade 0.10 Chi2
G1 6 (18%) 1 (6%)
G2 21 (62%) 8 (50%)
G3/4 7 (21%) 7 (44%)
CRP value, mean [mg/l], (IQR)1 12.4 (3.0-8.0) 24.7 (4.0-46.3) 0.04 Mann–Whitney
1at time of penile cancer surgery. Abbreviations: CRP C-reactive protein, BMI body mass index, LN lymph node, SD standard deviation.
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this difference was not statistically significant (p = 0.07,
Mann–Whitney test).Discussion
Elevated plasma CRP levels are not only associated with
an increased risk of cancer but also have been linked to
advanced disease with poor prognosis in various malig-
nancies [16-30]. In a recently published study we were
able to show that a high preoperative serum CRP level
was associated with poor survival in patients with penile
cancer [26]. In addition, this study shows that elevated
CRP levels are associated with higher tumor stages and
nodal disease, the most important prognostic factors for
penile carcinoma.
Our results are in line with those obtained for other
tumor entities. Chen et al. [16] found that high circulating
CRP levels correlated significantly with lymph node me-
tastasis and survival in patients with oral SCC. Ishizuka
et al. [32] evaluated several potential clinical factors and
biological markers in a large series of patients with locally
advanced colorectal cancer. Multivariate analysis identi-
fied high CRP levels as an indicator or predictor of both
nodal and distant metastasis in T3 colorectal cancer.
Neuss et al. [21] demonstrated that the preoperative
serum CRP level correlated significantly with the number
of lymph node metastases found during radical lymph
node dissection in stage III melanoma patients.Approximately 50% of the palpable lymph nodes in
patients with penile cancer ultimately prove to be tumor-
free after inguinal lymphadenectomy. The reason for the
low positive predictive value of palpable nodes is that their
enlargement can also caused by reactive changes upon
inflammatory reactions [2]. We therefore focused on the
subgroup of our patients with palpable nodes (n = 24),
all of whom underwent nodal dissection. Sixteen of them
(67%) actually did have lymph node metastasis. The ques-
tion was raised as to whether the CRP value might help to
distinguish between inflammation and cancer spread as
the cause of nodal enlargement. However, CRP level did
not differ significantly between the two entities in this
small subgroup, although it tended to be even higher in
the patients with nodal metastasis (mean, 24.7 vs. 6.4 mg/l).
This clearly indicates that the tumor itself seems to be
involved in the elevation of serum CRP levels and that
the phenomenon of elevated CRP in penile cancer is not
simply a consequence of superinfection.
Our study was not without limitations. First and fore-
most among them is its retrospective design, which pre-
cluded the systematic evaluation of important additional
prognostic factors such as microscopic lymphovascular and
perineural invasion, growth pattern, and anatomic site.
Moreover, superinfection of penile tumors was not docu-
mented thoroughly and thus, retrospectively, we could not
assess this potentially confounding factor. The study is also
limited by the lack of central pathologic review. Finally the
number of included patients was relatively small.
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In conclusion, we have shown that a high preoperative
serum CRP level is closely correlated with nodal disease
and could help identify patients with penile cancer
who may profit from inguinal lymph node dissection.
Nomograms have already been proposed to estimate
the cumulative risk of metastatic involvement in penile
cancer patients, using different clinical and pathological
parameters [33]. We will have to evaluate whether the
predictive significance of these models can be further
improved by including additional markers such as the
preoperative serum CRP level.
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